Guardant Health (NASDAQ:GH) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Key Points

• Guardant Health reported a quarterly earnings per share (EPS) of ($0.44), exceeding analysts' expectations by $0.08, with revenues of $232.09 million, up 31% year-over-year.
• Several brokerages have raised their price targets for the stock, with UBS Group increasing it from $65.00 to $70.00, reflecting strong investor sentiment.
• Insider trading activity has shown a decline, with CEO Amirali Talasaz selling 100,000 shares, decreasing his stake in the company by 4.83%.

Guardant Health (NASDAQ:GH - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.08, Briefing.com reports. The firm had revenue of $232.09 million during the quarter, compared to analyst estimates of $211.19 million. During the same quarter last year, the business posted ($0.84) earnings per share. The company's revenue for the quarter was up 31.0% on a year-over-year basis. Guardant Health updated its FY 2025 guidance to EPS.

Guardant Health Trading Up 4.5%

GH stock traded up $1.98 during midday trading on Tuesday, hitting $46.17. The stock had a trading volume of 1,503,558 shares, compared to its average volume of 2,317,278. The firm has a market cap of $5.76 billion, a P/E ratio of -13.78 and a beta of 1.43. Guardant Health has a 1-year low of $20.14 and a 1-year high of $53.42. The business has a fifty day moving average price of $47.33 and a two-hundred day moving average price of $45.05.

Wall Street Analyst Weigh In

GH has been the topic of several research analyst reports. Raymond James Financial increased their price target on shares of Guardant Health from $59.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, July 31st. Barclays increased their price target on shares of Guardant Health from $55.00 to $60.00 and gave the company an "overweight" rating in a report on Thursday, May 1st. Piper Sandler reaffirmed an "overweight" rating and set a $60.00 target price (up from $50.00) on shares of Guardant Health in a report on Tuesday, May 6th. TD Securities raised their target price on shares of Guardant Health from $56.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Finally, Stifel Nicolaus raised their target price on shares of Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Nineteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $54.95.

Insiders Place Their Bets

In other Guardant Health news, Director Myrtle S. Potter sold 2,626 shares of Guardant Health stock in a transaction on Monday, June 16th. The shares were sold at an average price of $49.70, for a total value of $130,512.20. Following the completion of the sale, the director directly owned 18,180 shares of the company's stock, valued at approximately $903,546. The trade was a 12.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ian T. Clark sold 6,672 shares of Guardant Health stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $48.38, for a total transaction of $322,791.36. Following the completion of the sale, the director directly owned 9,851 shares of the company's stock, valued at approximately $476,591.38. This trade represents a 40.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 235,516 shares of company stock valued at $11,848,754 over the last quarter. Company insiders own 6.10% of the company's stock.

Institutional Investors Weigh In On Guardant Health

An institutional investor recently bought a new position in Guardant Health stock. Empowered Funds LLC acquired a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 6,436 shares of the company's stock, valued at approximately $274,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.